Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter phase III randomized double-blind placebo-controlled study to evaluate the efficacy of two dose levels of DAB3891L-2 (9 and 18 mcg/kg/day) [denileukin diftitox; Ontak] in cutaneous T-cell lymphoma (CTCL) patients with stage Ia-III disease who, following less than or equal to 3 previous therapies, have recurrent or persistent disease that has been biopsy-documented to express CD25

Next Previous
X
Search
Trial Profile

A multicenter phase III randomized double-blind placebo-controlled study to evaluate the efficacy of two dose levels of DAB3891L-2 (9 and 18 mcg/kg/day) [denileukin diftitox; Ontak] in cutaneous T-cell lymphoma (CTCL) patients with stage Ia-III disease who, following less than or equal to 3 previous therapies, have recurrent or persistent disease that has been biopsy-documented to express CD25

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Cutaneous T-cell lymphoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 08 Mar 2010 Results published in JCO.
    • 04 Jun 2007 Primary endpoint 'Objective clinical response rate' has been met.
    • 05 Sep 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top